Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market Size in the 7MM is Expected to Grow Major Growth by 2034, estimates DelveInsight

DelveInsight's "Gastroenteropancreatic Neuroendocrine Tumors Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Gastroenteropancreatic Neuroendocrine Tumors Market by downloading the comprehensive report from DelveInsight @ Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report
• As per DelveInsight's assessments, the incidence of functional GEP-NET is more than that of nonfunctional GEPNET in the United States
• According to Dasari et al. (2017), the incidence rate of GEP-NETs in the United States was 3.56 cases per 100,000. Incidence rates of small intestinal, rectal, and pancreatic NETs were 1.05 cases per 100,000, 1.04 cases per 100,000, and 0.48 cases per 100,000, respectively. v According to Scherubl et al. (2013), the crude incidence rate of GEP NETs in Germany rose from 0.45 cases per 100,000 in 1976 to 2.5 cases per 100,000 in 2006.
• As per Masui et al. (2020), the age-adjusted overall incidence of gastro-entero-pancreatic neuroendocrineneoplasms (GEP-NEN) in Japan was 3.53 per 100,000.Most NENs in the esophagus or lungs were neuroendocrine carcinomas (NECs), while the majority of those in the duodenum, ileum, appendix and were grade 1 neuroendocrine tumors (NETs).
• As per Genus et al. (2019), among the 15,222 cases of NET diagnosed between 2013 and 2015, 50.7% were diagnosed with GEP-NENs, this patient cohort included both NETs and NECs, with the latter comprising 37% of all patients.
• The leading Gastroenteropancreatic Neuroendocrine Tumors Companies such as Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
• Promising Gastroenteropancreatic Neuroendocrine Tumors Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others.

Stay ahead in the competitive landscape of the Gastroenteropancreatic Neuroendocrine Tumors Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Gastroenteropancreatic Neuroendocrine Tumors Treatment Market Size- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Segmentation in the 7MM
• Total Gastroenteropancreatic Neuroendocrine Tumors Incident Cases
• Gastroenteropancreatic Neuroendocrine Tumors Grade-specific Cases
• Gastroenteropancreatic Neuroendocrine Tumors Tumor site-specific Cases
• Gastroenteropancreatic Neuroendocrine Tumors Stage-specific Cases
• Gastroenteropancreatic Neuroendocrine Tumors Symptom-specific Cases

Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumors epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumors Prevalence- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroenteropancreatic Neuroendocrine Tumors Treatment Market
Gastroenteropancreatic Neuroendocrine Tumors treatments usually induce tumor stabilization for a limited length of time. Enormous effort is being put into developing novel approaches to overcome treatment-related resistance in patients with advanced and progressive GEP-NETs. The relatively small number of patients included in clinical studies, as well as the relatively slow course of the disease, make it difficult to evaluate the response rates for new therapies and their influence on survival.

Gastroenteropancreatic Neuroendocrine Tumors Marketed Drugs
• LUTATHERA: Novartis
• SOMATULINE DEPOT: Ipsen Biopharmaceuticals

Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs
• CAM2029: Camurus AB
• ITM-11: ITM Isotope Technologies Munich

Discover the future of Gastroenteropancreatic Neuroendocrine Tumors Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Gastroenteropancreatic Neuroendocrine Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroenteropancreatic Neuroendocrine Tumors Drugs and Companies
• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• Lanreotide: Merck Sharp & Dohme
• arginine/lysine: Advanced Accelerator
• Temozolomide (TMZ): Ipsen
• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• CAM2029: Camurus AB
• Everolimus: Novartis
• PEN-221: Tarveda Therapeutics
• Lutathera: Progenics Pharmaceuticals
• Ibrutinib: Pharmacyclics

Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Gastroenteropancreatic Neuroendocrine Tumors Companies- Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
• Gastroenteropancreatic Neuroendocrine Tumors Therapies- LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others.
• Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL's views, Analyst's views, Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement

Explore the dynamics of the Gastroenteropancreatic Neuroendocrine Tumors Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Gastroenteropancreatic Neuroendocrine Tumors Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Gastroenteropancreatic Neuroendocrine Tumors Market Report Introduction
3. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance
4. Executive Summary of Gastroenteropancreatic Neuroendocrine Tumors
5. Gastroenteropancreatic Neuroendocrine Tumors Market Disease Background and Overview
6. Methodology
7. Gastroenteropancreatic Neuroendocrine Tumors Epidemiology and Patient Population
8. Patient Journey
9. Gastroenteropancreatic Neuroendocrine Tumors Marketed Drugs
10. Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs
11. Gastroenteropancreatic Neuroendocrine Tumors: Seven Major Market Analysis
12. KOL Views
13. SWOT Analysis
14. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs
15. Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.